Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives

DJ Angiolillo, A Fernandez-Ortiz, E Bernardo… - Journal of the American …, 2007 - jacc.org
Antiplatelet therapy is the cornerstone of treatment for patients with acute coronary
syndromes and/or undergoing percutaneous coronary interventions. Clopidogrel, in …

Significant mitral regurgitation left untreated at the time of aortic valve replacement: a comprehensive review of a frequent entity in the transcatheter aortic valve …

L Nombela-Franco, HB Ribeiro, M Urena… - Journal of the American …, 2014 - jacc.org
Significant mitral regurgitation (MR) is frequent in patients with severe aortic stenosis (AS). In
these cases, concomitant mitral valve repair or replacement is usually performed at the time …

[HTML][HTML] A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease

PW Serruys, P De Jaegere, F Kiemeneij… - … England Journal of …, 1994 - Mass Medical Soc
Background Balloon-expandable coronary-artery stents were developed to prevent coronary
restenosis after coronary angioplasty. These devices hold coronary vessels open at sites …

Clinical impact and evolution of mitral regurgitation following transcatheter aortic valve replacement: a meta-analysis

L Nombela-Franco, H Eltchaninoff, R Zahn, L Testa… - Heart, 2015 - heart.bmj.com
Objectives Mitral regurgitation (MR) is a common entity in patients with aortic stenosis
undergoing transcatheter aortic valve replacement (TAVR), but its influence on outcomes …

Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND (Trial on …

GBJ Mancini, GC Henry, C Macaya, BJ O'Neill… - Circulation, 1996 - Am Heart Assoc
Background Angiotensin-converting enzyme (ACE) inhibitors may exert some of their
benefits in the therapy of hypertension, congestive heart failure, and acute myocardial …

Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute …

SR Mehta, JF Tanguay, JW Eikelboom, SS Jolly… - The Lancet, 2010 - thelancet.com
Background Clopidogrel and aspirin are the most commonly used antiplatelet therapies for
percutaneous coronary intervention (PCI). We assessed the effect of various clopidogrel and …

Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial

PWJC Serruys, P de Feyter, C Macaya, N Kokott, J Puel… - Jama, 2002 - jamanetwork.com
ContextPercutaneous coronary intervention (PCI) is associated with excellent short-term
improvements in ischemic symptoms, yet only three fifths of PCI patients at 5 years and one …

Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II)

PW Serruys, B van Hout, H Bonnier, V Legrand… - The Lancet, 1998 - thelancet.com
Summary Background The multicentre, randomised Benestent-II study investigated a
strategy of implantation of a heparincoated Palmar-Schatz stent plus antiplatelet drugs …

Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies

R Moreno, C Fernández, R Hernández… - Journal of the American …, 2005 - jacc.org
Objectives: We compared the risk of stent thrombosis (ST) after drug-eluting stents (DES)
versus bare-metal stents (BMS), and tested the hypothesis that the risk of DES thrombosis is …

[HTML][HTML] Comparison of zotarolimus-eluting and everolimus-eluting coronary stents

PW Serruys, S Silber, S Garg… - New England journal …, 2010 - Mass Medical Soc
Background New-generation coronary stents that release zotarolimus or everolimus have
been shown to reduce the risk of restenosis. However, it is unclear whether there are …